Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus

Clinical Infectious Diseases

Volumn 56, Issue 9, 2013, Pages

  Matthews, Gail V ^a   Seaberg, Eric C ^h   Avihingsanon, Anchalee ^i,j   Bowden, Scott ^c   Dore, Gregory J ^a   Lewin, Sharon R ^d,e,f   Sasadeusz, Joe ^g   Revill, Peter A ^c   Littlejohn, Margaret ^c   Hoy, Jennifer F ^d,e,f   Finlayson, Robert ^b   Ruxrungtham, Kiat ^i,j   Saulynas, Melissa ^h   Locarnini, Stephen ^c   Thio, Chloe L ^h  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Taylor Square Private Clinic ^*  (Australia)

^c VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^d ALFRED HOSPITAL   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f BURNET INSTITUTE   (Australia)

^g ROYAL MELBOURNE HOSPITAL   (Australia)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^j CHULALONGKORN UNIVERSITY   (Thailand)

more..

Author keywords

adherence; antiretroviral therapy; hepatitis B; HIV

Indexed keywords

EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VIRUS DNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL PRACTICE; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MONOTHERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT RESPONSE; VIREMIA; VIRUS DETECTION;

ADENINE; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; AUSTRALIA; COINFECTION; DEOXYCYTIDINE; DNA, VIRAL; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; ORGANOPHOSPHONATES; THAILAND; TREATMENT FAILURE; UNITED STATES;

EID: 84876000229     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit002     Document Type: Article

References (14)

1. Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 2007; 7:402-9. (Pubitemid 46765200)
2. Matthews G, Cooper DA, Dore G. Improvements in parameters of end stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir. Antiviral Therapy 2007; 12:119-22. (Pubitemid 46340434)
3. Benhamou Y, Fleury H, Trimoulet P, et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 2006; 43:548-55.
4. Nelson M, Portsmouth S, Stebbing J, et al. An open-label study of tenofovir in HIV-1 and hepatitis B virus coinfected individuals. AIDS 2003; 17:F7-10.
5. Martin-Carbonero L, Teixeira T, Poveda E, et al. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. AIDS 2011; 25:73-9.
6. de Vries-Sluijs TE, Reijnders JG, Hansen BE, et al. Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology 2010; 139:1934-41.
7. Matthews GV, Seaberg E, Dore GJ, et al. Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudineexperienced HIV/HBV coinfected individuals. AIDS 2009; 23: 1707-15.
8. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42:121-30.
9. Schafer J. Analysis of incomplete multivariate data. New York: Chapman and Hall/CRC Press, 1997.
10. Matthews GV, Avihingsanon A, Lewin SR, et al. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology 2008; 48:1062-9.
11. Sheldon J, Camino N, Rodes B, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005; 10:727-34. (Pubitemid 41376852)
12. Delaney WEt, Ray AS, Yang H, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006; 50:2471-7. (Pubitemid 43993188)
13. Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 2005; 293:817-29. (Pubitemid 40250365)
14. Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 2008; 105:3879-84. (Pubitemid 351723493)